Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer

Journal of Chemotherapy

Volumn 19, Issue 5, 2007, Pages 570-576

  Rosati, Gerardo ^a,d   Cordio, S ^b   Caputo, G ^b   Condorelli, S ^b   Germano, D ^a   Mattina, M ^b   Amadio, P ^b   Reggiardo, G ^c   Manzione, L ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b Garibaldi Nesima Hospital   (Italy)

^c Medi Service   (Italy)

^d NONE   (Italy)

Author keywords

5 fluorouracil; Advanced gastric cancer; First line chemotherapy; Irinotecan; Leucovorin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 36549021636     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.5.570     Document Type: Article

References (26)

1. Gunderson LL, Donohue JH, Alberts SR. Cancer of the stomach. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Clinical Oncology. 3th ed. New York, Excerpta Medica. 2004: 1819-1862.
2. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
3. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 2000; 18: 4001-4003.
4. Ohtsu A, Shimada Y, Shirao K et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan clinical oncology group study (JCOG9205). J Clin Oncol 2003; 21: 54-59.
5. Kim NK, Park YS, Heo DS et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818.
6. Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993; 19: 29-44.
7. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group. J Clin Oncol 2000; 18: 2648-2657.
8. Futatsuki K, Wakui A, Nakao I et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 gastrointestinal cancer study group. Gan To Kagaku Ryoho 1994; 21: 1033-1038.
9. Kanat O, Evrensel T, Manavoglu O et al. Single-agent irinotecan as second-line treatment for advanced gastric cancer. Tumori 2003; 89: 405-407.
10. Köhne CH, Catane R, Klein B et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003; 89: 997-1001.
11. Enzinger PC, Kulke MH, Clark JW et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005; 50: 2218-2223.
12. Assersohn L, Brown G, Cunningham D et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15: 64-69.
13. Kim ST, Kang WK, Kang JH et al. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane-and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 2005; 92: 1850-1854.
14. Moehler M, Haas U, Siebler J et al. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs 2003; 14: 645-650.
15. Blanke CD, Haller DG, Benson AB et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol 2001; 12: 1575-1580.
16. Pozzo C, Barone C, Szanto J et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomised phase II study. Ann Oncol 2004; 15: 1773-1781.
17. Moehler M, Eimermacher A, Siebler J et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92: 2122-2128.
18. Dank M, Zaluski J, Barone C et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients. J Clin Oncol 2005; 23 (16S): 308s.
19. Maiello E, Gebbia V, Giuliani F et al. 5-fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Ann Oncol 2000; 11: 1045-1051.
20. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
21. Bouché O, Raoul JL, Bonnetain F et al. Randomized multicenter phase II trial of biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Fédération Francophone de Cancérologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22: 4319-4328.
22. Yilmaz U, Oztop I, Alacacioglu A et al. Irinotecan combined with infusional 5-Fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. Chemotherapy 2006; 52: 264-270.
23. Miller AB, Hoogstraten B, Staquet N. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
24. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-458.
25. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1989; 10: 1-10.
26. Lininger L, Gail M, Green S et al. Comparison of four tests for quality of survival curves in the presence of stratification and censoring. Biometrika 1979; 3: 419-428.